Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NASDAQ | Common Stock
Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States.
It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch.
The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
As of August 26, 2024, Agile Therapeutics, Inc. operates as a subsidiary of Exeltis USA, Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | 0.28 Increased by +104.69% | -0.51 Increased by +154.35% |
| Mar 28, 24 | -1.51 Increased by +69.80% | -0.92 Decreased by -64.13% |
| Nov 9, 23 | -0.27 Increased by +49.06% | -1.84 Increased by +85.33% |
| Aug 9, 23 | -2.15 Increased by +20.66% | -7.00 Increased by +69.29% |
| May 11, 23 | -5.91 Decreased by -56.35% | -7.50 Increased by +21.20% |
| Mar 22, 23 | -5.00 Increased by +37.50% | -11.50 Increased by +56.52% |
| Nov 7, 22 | -0.53 Increased by +92.64% | -0.44 Decreased by -20.45% |
| Aug 11, 22 | -2.71 Increased by +66.13% | -3.70 Increased by +26.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 5.58 M Increased by +1.33% | -11.87 M Decreased by -211.68% | Decreased by -212.91% Decreased by -207.60% |
| Mar 31, 24 | 5.72 M Increased by +49.91% | 1.28 M Increased by +135.57% | Increased by +22.46% Increased by +123.73% |
| Dec 31, 23 | 3.61 M Decreased by -9.56% | -4.47 M Increased by +66.34% | Decreased by -123.69% Increased by +62.78% |
| Sep 30, 23 | 6.66 M Increased by +121.92% | -799.00 K Increased by +96.38% | Decreased by -11.99% Increased by +98.37% |
| Jun 30, 23 | 5.50 M Increased by +158.84% | -3.81 M Increased by +68.83% | Decreased by -69.22% Increased by +87.96% |
| Mar 31, 23 | 3.81 M Increased by +116.52% | -3.61 M Increased by +69.33% | Decreased by -94.68% Increased by +85.83% |
| Dec 31, 22 | 4.00 M Increased by +163.94% | -13.28 M Increased by +43.15% | Decreased by -332.31% Increased by +78.46% |
| Sep 30, 22 | 3.00 M Increased by +133.26% | -22.05 M Decreased by -31.46% | Decreased by -734.48% Increased by +43.64% |